OMER OMEROS CORP US FDA Inspections 8-K Filing 2025 - Clinical Trials On May 6, 2025, Omeros Corporation announced that the FDA accepted its application for review of narsoplimab, intended for treating a serious blood-related condition after stem cell transplants.Get access to all SEC 8-K filings of the OMEROS CORP